Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
A phase 3 trial of Cyclophosphamide, Doxorubicin, Prednisone and Vincristine in non-Hodgkin lymphoma, run by Chipscreen Biosciences, Ltd., now recruiting.
Overview
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype is a phase 3 interventional study registered as NCT06947967 by Chipscreen Biosciences, Ltd., with 224 participants planned, started 2025-08-12 and due to reach its primary completion in 2032-12. Interventions recorded: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat and Placebo.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Shares Prednisone, Cyclophosphamide, Doxorubicin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Shares Prednisone, Vincristine, Doxorubicin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Shares Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Shares Cyclophosphamide, Doxorubicin and the tag pipeline.